MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-12-3140

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2013

Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.

Spreafico Anna, Tentler John J, Pitts Todd M, Tan Aik Choon, Gregory Mark A, Arcaroli John J, Klauck Peter J, McManus Martine C, Hansen Ryan J, Kim Jihye, Micel Lindsey N, Selby Heather M, Newton Timothy P, McPhillips Kelly L, Gustafson Daniel L, Degregori James V, Messersmith Wells A, Winn Robert A, Eckhardt S Gail

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: The mitogen-activated protein kinase (MAPK) pathway is a crucial regulator of cell proliferation, survival, and resistance to apoptosis. MEK inhibitors are being explored as a treatment option for patients with KRAS-mutant colorectal cancer who are not candidates for EGFR-directed therapies. Initial clinical results of MEK inhibitors have yielded limited single-agent activity in colorectal cancer, indicating that rational combination strategies are needed.

EXPERIMENTAL

DESIGN

In this study, we conducted unbiased gene set enrichment analysis and synthetic lethality screens with selumetinib, which identified the noncanonical Wnt/Ca++ signaling pathway as a potential mediator of resistance to the MEK1/2 inhibitor selumetinib. To test this, we used shRNA constructs against relevant WNT receptors and ligands resulting in increased responsiveness to selumetinib in colorectal cancer cell lines. Further, we evaluated the rational combination of selumetinib and WNT pathway modulators and showed synergistic antiproliferative effects in in vitro and in vivo models of colorectal cancer.

RESULTS

Importantly, this combination not only showed tumor growth inhibition but also tumor regression in the more clinically relevant patient-derived tumor explant (PDTX) models of colorectal cancer. In mechanistic studies, we observed a trend toward increased markers of apoptosis in response to the combination of MEK and WntCa(++) inhibitors, which may explain the observed synergistic antitumor effects.

CONCLUSIONS

These results strengthen the hypothesis that targeting both the MEK and Wnt pathways may be a clinically effective rational combination strategy for patients with metastatic colorectal cancer.

Для цитирования: Spreafico Anna, Tentler John J, Pitts Todd M, Tan Aik Choon, Gregory Mark A, Arcaroli John J, Klauck Peter J, McManus Martine C, Hansen Ryan J, Kim Jihye, Micel Lindsey N, Selby Heather M, Newton Timothy P, McPhillips Kelly L, Gustafson Daniel L, Degregori James V, Messersmith Wells A, Winn Robert A, Eckhardt S Gail. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013. DOI: 10.1158/1078-0432.ccr-12-3140.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.